DOC-MEK: A double blind randomized phase 2 trial of docetaxel with or without selumetinib in wild-type BRAF advanced melanoma.

A Gupta, S Love, A Schuh, M Shanyinde, JM Larkin, R Plummer, PD Nathan, S Danson, CH Ottensmeier, P Lorigan, L Collins, A Wise, R Asher, R Lisle, MR Middleton

    Research output: Contribution to journal › Article › peer-review

    Fingerprint

    Dive into the research topics of 'DOC-MEK: A double blind randomized phase 2 trial of docetaxel with or without selumetinib in wild-type BRAF advanced melanoma.'. Together they form a unique fingerprint.

    Pharmacology, Toxicology and Pharmaceutical Science